Immunotherapy of Autoimmune Diseases with Nonantibiotic Properties of Tetracyclines

다국어 초록 (Multilingual Abstract)

Tetracyclines, which have long been used as broad-spectrum antibiotics, also exhibit a variety of nonantibiotic activities including anti-inflammatory and immunomodulatory properties. Tetracyclines bind to the 30S ribosome of the bacteria and inhibit protein synthesis. Unlike antimicrobial activity, the primary molecular target for the nonantibiotic activity of tetracycline remains to be clarified. Nonetheless, the therapeutic efficacies of tetracyclines, particularly minocycline and doxycycline, have been demonstrated in various animal models of autoimmune disorders, such as multiple sclerosis, rheumatoid arthritis, and asthma. In this study, we summarized the anti-inflammatory and immunomodulatory activities of tetracyclines, focusing on the mechanisms underlying these activities. In addition, we highlighted the on-going or completed clinical trials with reported outcomes.

참고문헌 (Reference)

1 Garrido-Mesa N, "What is behind the non-antibiotic properties of minocycline" 67 : 18-30, 2013

2 Metz LM, "Trial of minocycline in a clinically isolated syndrome of multiple sclerosis" 376 : 2122-2133, 2017

3 O'Dell JR, "Treatment of early seropositive rheumatoid arthritis : doxycycline plus methotrexate versus methotrexate alone" 54 : 621-627, 2006

4 O'Dell JR, "Treatment of early seropositive rheumatoid arthritis : a two-year, double-blind comparison of minocycline and hydroxychloroquine" 44 : 2235-2241, 2001

5 Lee JH, "Tolerogenic dendritic cells are efficiently generated using minocycline and dexamethasone" 7 : 15087-, 2017

6 Yulug B, "Therapeutic role of rifampicin in Alzheimer's disease" 72 : 152-159, 2018

7 Kloppenburg M, "The tetracycline derivative minocycline differentially affects cytokine production by monocytes and T lymphocytes" 40 : 934-940, 1996

8 Yong VW, "The promise of minocycline in neurology" 3 : 744-751, 2004

9 Santa-Cecília FV, "The neuroprotective effect of doxycycline on neurodegenerative diseases" 35 : 981-986, 2019

10 Kloppenburg M, "The influence of tetracyclines on T cell activation" 102 : 635-641, 1995

11 Ingham E, "The effects of minocycline and tetracycline on the mitotic response of human peripheral blood-lymphocytes" 27 : 607-617, 1991

12 Snijders GF, "The effects of doxycycline on reducing symptoms in knee osteoarthritis : results from a triple-blinded randomised controlled trial" 70 : 1191-1196, 2011

13 Bernardino AL, "The antibiotics doxycycline and minocycline inhibit the inflammatory responses to the Lyme disease spirochete Borrelia burgdorferi" 199 : 1379-1388, 2009

14 Yrjänheikki J, "Tetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia" 95 : 15769-15774, 1998

15 Bahrami F, "Tetracyclines : drugs with huge therapeutic potential" 12 : 44-52, 2012

16 Attur MG, "Tetracycline up-regulates COX-2 expression and prostaglandin E2 production independent of its effect on nitric oxide" 162 : 3160-3167, 1999

17 D'Agostino P, "Tetracycline inhibits the nitric oxide synthase activity induced by endotoxin in cultured murine macrophages" 346 : 283-290, 1998

18 Chopra I, "Tetracycline antibiotics : mode of action, applications, molecular biology, and epidemiology of bacterial resistance" 65 : 232-260, 2001

19 Saleha T, "Tetracycline : classification, structure activity relationship and mechanism of action as a theranostic agent for infectious lesions-a mini review" 7 : 5787-5796, 2018

20 Brundula V, "Targeting leukocyte MMPs and transmigration : minocycline as a potential therapy for multiple sclerosis" 125 : 1297-1308, 2002

21 Hsieh CT, "Systemic lipopolysaccharide-induced pain sensitivity and spinal inflammation were reduced by minocycline in neonatal rats" 19 : 2947-, 2018

22 Smith GN Jr, "Specificity of inhibition of matrix metalloproteinase activity by doxycycline : relationship to structure of the enzyme" 42 : 1140-1146, 1999

23 Frankwich K, "Proof of concept: matrix metalloproteinase inhibitor decreases inflammation and improves muscle insulin sensitivity in people with type 2 diabetes" 9 : 35-, 2012

24 Mei XP, "Post-injury administration of minocycline : an effective treatment for nerve-injury induced neuropathic pain" 70 : 305-312, 2011

25 Beringer PM, "Pharmacokinetics of doxycycline in adults with cystic fibrosis" 56 : 70-74, 2012

26 Dalm D, "Nonantibiotic properties of tetracyclines : structural basis for inhibition of secretory phospholipase A2" 398 : 83-96, 2010

27 Sakurai H, "Nitric oxide production and inducible nitric oxide synthase expression in inflammatory arthritides" 96 : 2357-2363, 1995

28 Schmidt HH, "NO at work" 78 : 919-925, 1994

29 Castro JE, "Modulation of cytokine and cytokine receptor/antagonist by treatment with doxycycline and tetracycline in patients with dengue fever" 2011 : 370872-, 2011

30 Tikka T, "Minocycline, a tetracycline derivative, is neuroprotective against excitotoxicity by inhibiting activation and proliferation of microglia" 21 : 2580-2588, 2001

31 Ataie-Kachoie P, "Minocycline suppresses interleukine-6, its receptor system and signaling pathways and impairs migration, invasion and adhesion capacity of ovarian cancer cells : in vitro and in vivo studies" 8 : e60817-, 2013

32 Niimi N, "Minocycline suppresses experimental autoimmune encephalomyelitis by increasing tissue inhibitors of metalloproteinases" 33 : 612-620, 2013

33 Szeto GL, "Minocycline suppresses activation of nuclear factor of activated T cells 1(NFAT1)in human CD4+ T cells" 286 : 11275-11282, 2011

34 Golub LM, "Minocycline reduces gingival collagenolytic activity during diabetes. Preliminary observations and a proposed new mechanism of action" 18 : 516-526, 1983

35 Kim N, "Minocycline promotes the generation of dendritic cells with regulatory properties" 7 : 52818-52831, 2016

36 Kielian T, "Minocycline modulates neuroinflammation independently of its antimicrobial activity in Staphylococcus aureus-induced brain abscess" 171 : 1199-1214, 2007

37 He Y, "Minocycline inhibits microglial activation and protects nigral cells after 6-hydroxydopamine injection into mouse striatum" 909 : 187-193, 2001

38 Kalish RS, "Minocycline inhibits antigen processing for presentation to human T cells : additive inhibition with chloroquine at therapeutic concentrations" 113 : 270-277, 2004

39 Kloppenburg M, "Minocycline in active rheumatoid arthritis. A double-blind, placebo-controlled trial" 37 : 629-636, 1994

40 Nikodemova M, "Minocycline down-regulates MHC II expression in microglia and macrophages through inhibition of IRF-1 and protein kinase C(PKC)alpha/betaII" 282 : 15208-15216, 2007

41 Huang TY, "Minocycline attenuates experimental colitis in mice by blocking expression of inducible nitric oxide synthase and matrix metalloproteinases" 237 : 69-82, 2009

42 Giuliani F, "Minocycline attenuates T cell and microglia activity to impair cytokine production in T cell-microglia interaction" 78 : 135-143, 2005

43 Stirling DP, "Minocycline as a neuroprotective agent" 11 : 308-322, 2005

44 Kim HS, "Minocycline and neurodegenerative diseases" 196 : 168-179, 2009

45 Wang X, "Matrix metalloproteinases, vascular remodeling, and vascular disease" 81 : 241-330, 2018

46 Baugh MD, "Matrix metalloproteinase levels are elevated in inflammatory bowel disease" 117 : 814-822, 1999

47 Yoon-Seong Kim, "Matrix Metalloproteinases, New Insights into the Understanding of Neurodegenerative Disorders" 한국응용약물학회 20 (20): 133-143, 2012

48 Pruzanski W, "Inhibition of enzymatic activity of phospholipases A2 by minocycline and doxycycline" 44 : 1165-1170, 1992

49 Popovic N, "Inhibition of autoimmune encephalomyelitis by a tetracycline" 51 : 215-223, 2002

50 Hahn JN, "Impact of minocycline on extracellular matrix metalloproteinase inducer, a factor implicated in multiple sclerosis immunopathogenesis" 197 : 3850-3860, 2016

51 Patel A, "Immunomodulatory effect of doxycycline ameliorates systemic and pulmonary inflammation in a murine polymicrobial sepsis model" 43 : 1035-1043, 2020

52 Metz LM, "Glatiramer acetate in combination with minocycline in patients with relapsing--remitting multiple sclerosis : results of a Canadian, multicenter, double-blind, placebo-controlled trial" 15 : 1183-1194, 2009

53 Lin M, "Efficacy of subantimicrobial dose doxycycline for moderate-to-severe and active Graves' orbitopathy" 2015 : 285698-, 2015

54 Mazdeh M, "Efficacy of doxycycline as add-on to interferon beta-1a in treatment of multiple sclerosis" 11 : 70-73, 2012

55 Brandt KD, "Effects of doxycycline on progression of osteoarthritis : results of a randomized, placebo-controlled, double-blind trial" 52 : 2015-2025, 2005

56 Prins HJ, "Effects of doxycycline on local and systemic inflammation in stable COPD patients, a randomized clinical trial" 110 : 46-52, 2016

57 Joks R, "Effect of tetracyclines on IgE allergic responses and asthma" 5 : 221-228, 2011

58 Thong YH, "Effect of tetracycline treatment on immunological responses in mice" 39 : 728-732, 1980

59 Clark WM, "Doxycycline treatment reduces ischemic brain damage in transient middle cerebral artery occlusion in the rat" 9 : 103-108, 1997

60 Cazalis J, "Doxycycline reduces lipopolysaccharide-induced inflammatory mediator secretion in macrophage and ex vivo human whole blood models" 79 : 1762-1768, 2008

61 Jantzie LL, "Doxycycline inhibits proinflammatory cytokines but not acute cerebral cytogenesis after hypoxia-ischemia in neonatal rats" 35 : 20-32, 2010

62 Xu X, "Doxycycline improves clinical outcomes during cystic fibrosis exacerbations" 49 : 1601102-, 2017

63 Ali I, "Doxycycline as potential anti-cancer agent" 17 : 1617-1623, 2017

64 Henehan M, "Doxycycline as an anti-inflammatory agent : updates in dermatology" 31 : 1800-1808, 2017

65 Machado LS, "Delayed minocycline inhibits ischemia-activated matrix metalloproteinases 2 and 9 after experimental stroke" 7 : 56-, 2006

66 Minagar A, "Combination therapy with interferon beta-1a and doxycycline in multiple sclerosis : an openlabel trial" 65 : 199-204, 2008

67 Wu DC, "Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine mouse model of Parkinson disease" 22 : 1763-1771, 2002

68 Leite LM, "Anti-inflammatory properties of doxycycline and minocycline in experimental models : an in vivo and in vitro comparative study" 19 : 99-110, 2011

69 Loeb MB, "A randomized, controlled trial of doxycycline and rifampin for patients with Alzheimer's disease" 52 : 381-387, 2004

70 Pardo CA, "A pilot open-label trial of minocycline in patients with autism and regressive features" 5 : 9-, 2013

71 Amin AR, "A novel mechanism of action of tetracyclines : effects on nitric oxide synthases" 93 : 14014-14019, 1996

72 Golub LM, "A non-antimicrobial tetracycline inhibits gingival matrix metalloproteinases and bone loss in Porphyromonas gingivalis-induced periodontitis in rats" 732 : 96-111, 1994